Mechanism of Action and Synthesis of Mezlocillin

Muralinath E., Yerikala Ramesh

Abstract


Mezlocillin is an extended-spectrum, semisynthetic ureidopenicillin antibiotic.

Overview & Mechanism

  • •                     Class: Extended-spectrum beta-lactam penicillin/acylureido.
  • •                     Mechanism: Produces a bactericidal action by preventing the formation of bacterial cell walls.
  • •                     Spectrum: Effective against a variety of anaerobic bacteria (such as Bacteroides fragilis), Gram-negative bacilli (such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella, and Proteus), and Gram-positive cocci (such as streptococci and enterococci).

Pharmacokinetics

  • •                     Administration: Intramuscular (IM) or intravenous (IV) injection (poorly absorbed orally).
  • •                     Half-life: 60–66 minutes, or around 0.7–1.1 hours.
  • •                     Excretion: Mainly removed via biliary excretion and the kidneys (urine).
  • The range of protein binding is 16% to 42%.

Clinical Indications

  • Infections of the lower respiratory tract
  • UTIs, or urinary tract infections
  • Infections of the skin and skin structure
  • Peritonitis and intra-abdominal infections
  • Infections related to gynecology
  • Infections of the bones and joints (osteomyelitis)
  • Bacteremia or septicemia

 


References


Schroeck, W., Furtwaengier, H. R., Koenig, H. B., & Metzer, K. G. (1973). German Offenlegungsschrift No. 2,318,955. Chemical Abstracts, 82, 31313b (1975).

Koenig, H. B., Metzer, K. G., Offe, H. A., & Schroeck, W. (1982). [Article title not provided]. European Journal of Medicinal Chemistry, 17, 59.

Kristof, R., Clusmann, H., Koehler, W., Fink, K., & Schramm, J. (1998). Treatment of accidental high dose intraventricular mezlocillin application by cerebrospinal fluid exchange. Journal of Neurology, Neurosurgery & Psychiatry, 64(3), 379–381. https://doi.org/10.1136/jnnp.64.3.379

McCormick, P., Greenslade, L., Kibbler, C., Chin, J., Burroughs, A., & McIntyre, N. (1997). A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology, 25(4), 833–836. https://doi.org/10.1002/hep.510250408

Rohde, B., Werner, U., Hickstein, H., Ehmcke, H., & Drewelow, B. (1997). Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure. European Journal of Clinical Pharmacology, 53(2), 111–115. https://doi.org/10.1007/s002280050347


Refbacks

  • There are currently no refbacks.